Investor Relations Activities
Our investor relations work in 2010 again focused on ensuring the comprehensive, transparent and timely provision of information to capital markets. This includes disclosing of information about strategy and management principles of Fresenius Medical Care, its operating and financial business development, as well as its future prospects to a wide audience. This encompasses its shareholders, other capital market participants and analysts as well as employees, journalists and the general public. Our aim in doing this is to communicate our Company’s business performance in an appropriate and precise way to allow existing and potential investors to make informed investment decisions and to provide other target groups with a balanced overview of the Company, its activities, and its plans for the future. We want to make a significant contribution to increasing the value of Fresenius Medical Care in the long-term by means of effective financial communications.
BASIC SHARE DATA
|Share type||No par value bearer share||No par value bearer share|
|Stock exchange/Ticker symbol|
|Germany: Frankfurt Stock Exchange/Prime Standard||FME||FME3|
|U.S.: New York Stock Exchange (NYSE)||FMS||FMS/P|
|German security identification codes|
|Securities No. (WKN)||578580||578583|
|CUSIP No. (NYSE)||358029106||358029205|
|Frankfurt Stock Exchange||FMEG.F||FMEG_p.F|
|Xetra||FME GY||FME3 GY|
|Frankfurt Stock Exchange||FME GR||FME3 GR|
|ADR NYSE||FMS US||FMS/P US|
Fresenius Medical Care is committed to ensuring that all shareholders have equal and timely access to important information that could have a bearing on our share price. All channels of communication are designed to avoid selectively distributing this sort of information. Depending on the information and recipient, the Company selects the communication channel that is most suitable at that point in time for communicating effectively. In doing so, we fulfil the requirements of the applicable laws and relevant guidelines we are held to observe in both the U.S. and Germany. These include the regulations of Deutsche Börse and the New York Stock Exchange as well as the German Securities Trading Act (Wertpapierhandelsgesetz, WpHG), the German Corporate Governance Code and the Sarbanes-Oxley Act. More on this and other corporate governance issues can be found here
Fresenius Medical Care does not generally respond to rumors concerning the Company unless these contain material information about the Company or are expected to have an significant impact on the Company’s share price or corresponding trading activities.
In 2010, we again intensified our communication with financial analysts as well as with institutional and retail investors worldwide. Financial analysts continue to express great interest in our Company. This is reflected in the fact that we are covered by around 35 equity analysts, so-called sell-side analysts.
In the year under review, we presented Fresenius Medical Care in more than 800 one-on-ones with analysts and investors and answered questions about our business performance and the Company’s future. In addition, we showcased the Company and its perspectives at 22 road shows and 25 investment conferences around the globe. Retail investors also play an important role. For this reason, we attended several retail investment events including those organized by Germany’s leading association of retail investors, Deutsche Schutzvereinigung für Wertpapierbesitz (DSW), and Schutzgemeinschaft der Kapitalanleger (SDK). We also held a Capital Market Day in London to provide detailed information about our Company to investors and analysts. During the two-day event, participants were updated on the latest important business developments: the new products and processes that Fresenius Medical Care is working on, how business and the dialysis market as a whole have performed in each region, and the targets the Company has set for the next few years. One of the main points of interest for participants was Fresenius Medical Care assesses the new bundled reimbursement system for dialysis in the U.S. and the opportunities that this new system will offer the Company.
2010 was another successful year for the Investor Relations department at Fresenius Medical Care. Our Company received a number of awards for its outstanding investor relations work. “Capital” magazine and the DVFA (Society of Investment Professionals in Germany) recognized Fresenius Medical Care as having the second best IR work in the DAX. A survey carried out by the U.S. magazine “Institutional Investor” ranked our Company highest in the “healthcare” category in Europe for the third year in succession. Our annual report for 2009 also won seventh place in the DAX in a competition held by “manager magazin” and came top in the “Design” category.
On our web site www.fmc-ag.com we disclose the following information, among others:
- Price information for our shares listed at the Frankfurt and the New York stock exchanges
- Publications, e.g. quarterly reports, annual reports, investor news, and ad hoc news
- Full-year and quarterly earnings releases, e.g. live webcasts of analyst meetings and conference calls, corresponding information and presentation material
- Live webcasts of the CEO’s speech at the Annual General Meeting
- Financial calendar with information on reporting, the Annual General Meeting and further events
- Direct communication with us via e-mail with the possibility of automatic updates regarding Company developments.
key figures of Fresenius Medical Care'S ORDINARY SHARE
|12010: Proposal to be approved by the Annual General Meeting on May 12, 2011. 2Weighted average of outstanding shares. For a more detailed version, please refer to the five-year summary.|
|Share capital||in $ THOUS||369,002||365,672||363,076||361,384||359,527|
|Number of shares||in M||298.28||295.75||293.93||292.79||291.45|
|Closing prices (Xetra trading)|
|Year-end price||in €||43.23||36.94||33.31||36.69||33.66|
|Average daily trading volume||Shares||824,535||1,040,200||1,498,696||1,676,946||1,311,126|
|Year-end price||in $||57.69||53.01||47.18||52.75||44.43|
|Year-end||in € M||13,143||11,045||9,919||10,876||9,928|
|Year-end||in $ M||17,270||15,911||13,787||16,010||13,075|
|Exchange rate||$ to €||1.3141||1.4406||1.3900||1.4720||1.3170|
|Dividend yield||in %||1.5||1.7||1.7||1.5||1.4|
|Total dividend amount||in € M||197||183||173||160||139|
|Earnings per share (EPS)|
|Earnings per share (EPS)||in $||3.25||2.99||2.75||2.43||1.82|